NCT01726946View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Chronic Hepatitis C
Interventions
DRUG

VX-135

12 weeks of VX-135

DRUG

ribavirin

12 weeks of ribavirin

Trial Locations (6)

Unknown

California, La Jolla

Florida, Orlando

Georgia, Marietta

Tennessee, Germantown

Texas, Arlington

Texas, Houston

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT01726946 - A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C | Biotech Hunter | Biotech Hunter